275 related articles for article (PubMed ID: 35322126)
41. MutLα heterodimers modify the molecular phenotype of Friedreich ataxia.
Ezzatizadeh V; Sandi C; Sandi M; Anjomani-Virmouni S; Al-Mahdawi S; Pook MA
PLoS One; 2014; 9(6):e100523. PubMed ID: 24971578
[TBL] [Abstract][Full Text] [Related]
42.
Lam C; Gilliam KM; Rodden LN; Schadt KA; Lynch DR; Bidichandani S
J Med Genet; 2023 Aug; 60(8):797-800. PubMed ID: 36635061
[TBL] [Abstract][Full Text] [Related]
43. Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohort.
Lynch DR; Rojsajjakul T; Subramony SH; Perlman SL; Keita M; Mesaros C; Blair IA
J Neurol; 2024 Apr; 271(4):1844-1849. PubMed ID: 38063871
[TBL] [Abstract][Full Text] [Related]
44. FXN methylation predicts expression and clinical outcome in Friedreich ataxia.
Evans-Galea MV; Carrodus N; Rowley SM; Corben LA; Tai G; Saffery R; Galati JC; Wong NC; Craig JM; Lynch DR; Regner SR; Brocht AF; Perlman SL; Bushara KO; Gomez CM; Wilmot GR; Li L; Varley E; Delatycki MB; Sarsero JP
Ann Neurol; 2012 Apr; 71(4):487-97. PubMed ID: 22522441
[TBL] [Abstract][Full Text] [Related]
45. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.
Rai M; Soragni E; Chou CJ; Barnes G; Jones S; Rusche JR; Gottesfeld JM; Pandolfo M
PLoS One; 2010 Jan; 5(1):e8825. PubMed ID: 20098685
[TBL] [Abstract][Full Text] [Related]
46. Multicellular models of Friedreich ataxia.
Puccio H
J Neurol; 2009 Mar; 256 Suppl 1():18-24. PubMed ID: 19283346
[TBL] [Abstract][Full Text] [Related]
47. Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia.
Ouellet DL; Cherif K; Rousseau J; Tremblay JP
Gene Ther; 2017 May; 24(5):265-274. PubMed ID: 28024081
[TBL] [Abstract][Full Text] [Related]
48. Generation of induced pluripotent stem cell lines from Friedreich ataxia patients.
Liu J; Verma PJ; Evans-Galea MV; Delatycki MB; Michalska A; Leung J; Crombie D; Sarsero JP; Williamson R; Dottori M; Pébay A
Stem Cell Rev Rep; 2011 Sep; 7(3):703-13. PubMed ID: 21181307
[TBL] [Abstract][Full Text] [Related]
49. Stalled DNA Replication Forks at the Endogenous GAA Repeats Drive Repeat Expansion in Friedreich's Ataxia Cells.
Gerhardt J; Bhalla AD; Butler JS; Puckett JW; Dervan PB; Rosenwaks Z; Napierala M
Cell Rep; 2016 Aug; 16(5):1218-1227. PubMed ID: 27425605
[TBL] [Abstract][Full Text] [Related]
50. Removal of the GAA repeat in the heart of a Friedreich's ataxia mouse model using CjCas9.
Yaméogo P; Gérard C; Majeau N; Tremblay JP
Gene Ther; 2023 Aug; 30(7-8):612-619. PubMed ID: 36781946
[TBL] [Abstract][Full Text] [Related]
51. Frataxin deficiency alters gene expression in Friedreich ataxia derived IPSC-neurons and cardiomyocytes.
Angulo MB; Bertalovitz A; Argenziano MA; Yang J; Patel A; Zesiewicz T; McDonald TV
Mol Genet Genomic Med; 2023 Jan; 11(1):e2093. PubMed ID: 36369844
[TBL] [Abstract][Full Text] [Related]
52. Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia.
Gottesfeld JM
Neurotherapeutics; 2019 Oct; 16(4):1032-1049. PubMed ID: 31317428
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription.
De Biase I; Chutake YK; Rindler PM; Bidichandani SI
PLoS One; 2009 Nov; 4(11):e7914. PubMed ID: 19956589
[TBL] [Abstract][Full Text] [Related]
54. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure.
Bidichandani SI; Ashizawa T; Patel PI
Am J Hum Genet; 1998 Jan; 62(1):111-21. PubMed ID: 9443873
[TBL] [Abstract][Full Text] [Related]
55. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design.
Saccà F; Puorro G; Antenora A; Marsili A; Denaro A; Piro R; Sorrentino P; Pane C; Tessa A; Brescia Morra V; Cocozza S; De Michele G; Santorelli FM; Filla A
PLoS One; 2011 Mar; 6(3):e17627. PubMed ID: 21412413
[TBL] [Abstract][Full Text] [Related]
56. Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.
Chutake YK; Lam CC; Costello WN; Anderson MP; Bidichandani SI
Nucleic Acids Res; 2016 Jun; 44(11):5095-104. PubMed ID: 26896803
[TBL] [Abstract][Full Text] [Related]
57. Evidence for chromosome fragility at the frataxin locus in Friedreich ataxia.
Kumari D; Hayward B; Nakamura AJ; Bonner WM; Usdin K
Mutat Res; 2015 Nov; 781():14-21. PubMed ID: 26379101
[TBL] [Abstract][Full Text] [Related]
58. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAA⋅TTC triplet repeat instability.
Ku S; Soragni E; Campau E; Thomas EA; Altun G; Laurent LC; Loring JF; Napierala M; Gottesfeld JM
Cell Stem Cell; 2010 Nov; 7(5):631-7. PubMed ID: 21040903
[TBL] [Abstract][Full Text] [Related]
59. Central role and mechanisms of β-cell dysfunction and death in friedreich ataxia-associated diabetes.
Cnop M; Igoillo-Esteve M; Rai M; Begu A; Serroukh Y; Depondt C; Musuaya AE; Marhfour I; Ladrière L; Moles Lopez X; Lefkaditis D; Moore F; Brion JP; Cooper JM; Schapira AH; Clark A; Koeppen AH; Marchetti P; Pandolfo M; Eizirik DL; Féry F
Ann Neurol; 2012 Dec; 72(6):971-82. PubMed ID: 23280845
[TBL] [Abstract][Full Text] [Related]
60. Gene-based approaches toward Friedreich ataxia therapeutics.
Hebert MD; Whittom AA
Cell Mol Life Sci; 2007 Dec; 64(23):3034-43. PubMed ID: 17828464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
